Literature DB >> 7795227

Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. The French Network on the behalf of INSERM.

S Gandrille1, J S Greengard, M Alhenc-Gelas, I Juhan-Vague, J F Abgrall, B Jude, J H Griffin, M Aiach.   

Abstract

Because multiple risk factors in one patient may increase the clinical expression of thrombophilia, we assessed the presence in protein C-deficient patients of the factor V Arg 506 Gln mutation responsible for activated protein C resistance. Using a strategy allowing rapid screening of factor V exon 10, we studied 113 patients with protein C deficiency and 104 healthy volunteers. We detected the Arg 506 Gln mutation in 15 patients (14%) and in one healthy subject (1%). We identified a previously unpublished sequence variation leading to an Arg 485 Lys substitution in three normal subjects and seven protein C-deficient patients. A significant difference in the allelic frequency of the Arg 506 Gln factor V mutation was found between protein C-deficient patients heterozygous for an identified protein C mutation (n = 84; allelic frequency, 4.8%) and protein C-deficient patients with no identified mutation in the protein C gene coding regions (n = 25; allelic frequency, 14%). The results demonstrate that a significant subset of thrombophilic patients has multiple genetic risk factors although additional secondary genetic risk factors remain to be identified for the majority of symptomatic protein C-deficient patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7795227

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Congenital thrombophilia and thrombosis: a study in a single centre.

Authors:  S E Lawson; D Butler; M S Enayat; M D Williams
Journal:  Arch Dis Child       Date:  1999-08       Impact factor: 3.791

Review 2.  Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease.

Authors:  David N Cooper; Michael Krawczak; Constantin Polychronakos; Chris Tyler-Smith; Hildegard Kehrer-Sawatzki
Journal:  Hum Genet       Date:  2013-07-03       Impact factor: 4.132

Review 3.  Delineating the Hemostaseome as an aid to individualize the analysis of the hereditary basis of thrombotic and bleeding disorders.

Authors:  Kim Fechtel; Marika L Osterbur; Hildegard Kehrer-Sawatzki; Peter D Stenson; David N Cooper
Journal:  Hum Genet       Date:  2011-05-03       Impact factor: 4.132

4.  APCR, factor V gene known and novel SNPs and adverse pregnancy outcomes in an Irish cohort of pregnant women.

Authors:  Sara Sedano-Balbás; Mark Lyons; Brendan Cleary; Margaret Murray; Geraldine Gaffney; Majella Maher
Journal:  BMC Pregnancy Childbirth       Date:  2010-03-10       Impact factor: 3.007

5.  An unknown genetic defect increases venous thrombosis risk, through interaction with protein C deficiency.

Authors:  S J Hasstedt; E G Bovill; P W Callas; G L Long
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

6.  Acquired activated protein C resistance, thrombophilia and adverse pregnancy outcomes: a study performed in an Irish cohort of pregnant women.

Authors:  Sara Sedano-Balbás; Mark Lyons; Brendan Cleary; Margaret Murray; Geraldine Gaffney; Majella Maher
Journal:  J Pregnancy       Date:  2011-08-14

7.  Genetic association of PROC variants with pulmonary embolism in Northern Chinese Han population.

Authors:  Zengliang Wang; Tianhe Wang; Jianyong Chang; Hua Li; Chengdong Wang; Yongyong Li; Xuhe Lang; Shimei Jing; Guoqing Zhang; Yuting Wang
Journal:  Springerplus       Date:  2016-02-24

8.  Acquired factor V deficiency in a patient with a urinary tract infection presenting with haematuria followed by multiple haemorrhages with an extremely low level of factor V inhibitor: a case report and review of the literature.

Authors:  Xiangyu Wang; Xuemei Qin; Yuan Yu; Ran Wang; Xinguang Liu; Min Ji; Minran Zhou; Chunyan Chen
Journal:  Blood Coagul Fibrinolysis       Date:  2017-06       Impact factor: 1.276

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.